EcoDrugPlus

Calcium Voltage-Gated Channel Auxiliary Subunit Gamma 2

Ensembl ID : ENSACIG00000004673
Gene Symbol: CACNG2
1 Cross references
208 Possible Orthologues:

Calcium Voltage-Gated Channel Auxiliary Subunit Gamma 2

Ensembl ID : ENSACIG00000010789
Gene Symbol: CACNG2
2 Cross references
212 Possible Orthologues:

Calcium Voltage-Gated Channel Auxiliary Subunit Gamma 4

Ensembl ID : ENSACIG00000006355
Gene Symbol: CACNG4
1 Cross references
189 Possible Orthologues:

Calcium Voltage-Gated Channel Auxiliary Subunit Gamma 5

Ensembl ID : ENSACIG00000021926
Gene Symbol: CACNG5
1 Cross references
172 Possible Orthologues:

Calcium Voltage-Gated Channel Auxiliary Subunit Gamma 6

Ensembl ID : ENSACIG00000005771
Gene Symbol: CACNG6
1 Cross references
177 Possible Orthologues:

Calcium Voltage-Gated Channel Auxiliary Subunit Gamma 7

Ensembl ID : ENSACIG00000005803
Gene Symbol: CACNG7
1 Cross references
190 Possible Orthologues:

Calcium Voltage-Gated Channel Auxiliary Subunit Gamma 8

Ensembl ID : ENSACIG00000005787
Gene Symbol: CACNG8
1 Cross references
163 Possible Orthologues:

Calcium Voltage-Gated Channel Subunit Alpha1 A

Ensembl ID : ENSACIG00000006203
Gene Symbol: CACNA1A
1 Cross references
198 Possible Orthologues:

Calcium Voltage-Gated Channel Subunit Alpha1 B

Ensembl ID : ENSACIG00000020442
Gene Symbol: CACNA1B
1 Cross references
214 Possible Orthologues:

Calcium Voltage-Gated Channel Subunit Alpha1 D

Ensembl ID : ENSACIG00000001592
Gene Symbol: CACNA1D
2 Cross references
210 Possible Orthologues:

Calcium Voltage-Gated Channel Subunit Alpha1 E

Ensembl ID : ENSACIG00000007982
Gene Symbol: CACNA1E
2 Cross references
214 Possible Orthologues:

Calcium Voltage-Gated Channel Subunit Alpha1 E

Ensembl ID : ENSACIG00000018187
Gene Symbol: CACNA1E
1 Cross references
206 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).